Shots:

• The P-III (OLYMPIA 2) trial evaluating the efficacy, safety, PK & immunogenicity of nemolizumab as monothx. vs PBO in 540 patients aged 18yrs. with PN after 16wk. treatment period
• The trial met all 1EPs & 2EPs i.e., 38% vs 11% of patients showed clearance or almost-clearance of skin lesions as assessed by using the IGA score, 56% vs 21% achieved a 4-point reduction in itch as measured by PP-NRS score. The safety profile was consistent with the P-II trial results
• Nemolizumab also showed a positive benefit-risk balance & has been approved in Japan for pruritus associated with AD and is under clinical development in many countries globally. The therapy has received BTD from the US FDA for pruritus associated PN

Ref: Galderma | Image: Galderma